Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesGenomic Sequencing Procedures and Other Molecular Multianalyte AssaysCPT cpt-81463-liquid-biopsy-cfdna-solid-tumor-panel
    Ask Trek AI about this page

    CPT 81463: Liquid Biopsy cfDNA Genomic Panel for Solid Tumors

    Commercial payers pay $1192 on average nationally for this procedure.

    CPT code 81463 describes a laboratory liquid biopsy genomic sequencing panel performed on a serum specimen to detect cell-free DNA (cfDNA) alterations — including sequence variants, copy number variants, and microsatellite instability (MSI) — that inform diagnosis and treatment of solid organ tumors; service type: genomic sequence analysis of cfDNA; typical site of service: clinical laboratory or reference molecular diagnostics laboratory using a serum sample.

    For related coverage guidance, see recent payer policy updates: Minimal Residual Disease (MRD) Testing for Cancer, Biomarker Testing Mandate, Prenatal (Fetal) Diagnostic Testing.

    Customize your policy alerts

    Sign up for cpt 81463 policy alerts

    Get alerted when payer policies referencing 81463 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    National Reimbursement Benchmarks

    National commercial rates for CPT 81463 cluster around BUCA’s average commercial benchmark of $1,192.40, with notable variation by carrier. Blue Cross Blue Shield (BCBS) and Cigna show higher central tendencies (medians $1,150.30 and $1,545.90 respectively), while Aetna and UnitedHealth Group sit lower on median. Cigna and BCBS present high ceilings (max $4,346.50 and $2,789.20) that pull their means up above BUCA’s average, indicating some outlier high contracts among commercial payers.

    Examining dispersion (P75 minus P25) highlights where rates are most and least concentrated: Blue Cross Blue Shield has the widest interquartile spread at $575.80 ($1,524.70 - $934.90), followed by Cigna at $1,268.20 ($1,963.20 - $695.50) and BUCA at $597.60 ($1,497.60 - $790.20). UnitedHealth Group is the tightest at $679.30 ($1,345.30 - $565.00), with Aetna’s spread at $427.10 ($1,103.20 - $676.10), indicating relatively more compressed commercial contracting for Aetna and UnitedHealth Group compared with BCBS and Cigna.

    Table of contents

    Progress1 / 8

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools
    National Payer Mean Reimbursement Rates

    State Reimbursement Rates

    State: Alaska1 / 51

    Rate by payer

    Clinical & Coding Specifications

    Clinical Context

    A 62-year-old patient with a history of rectal adenocarcinoma presents with rising carcinoembryonic antigen (CEA) on surveillance and new, nonspecific abdominal symptoms. The treating oncologist orders a circulating tumor DNA (cfDNA) liquid biopsy to assess for actionable genomic alterations and microsatellite instability (MSI) status to guide systemic therapy selection and determine eligibility for targeted agents. A peripheral serum specimen is collected in the outpatient laboratory or clinic, processed by phlebotomy staff, and sent to the molecular pathology laboratory. The laboratory analyst performs extraction of cell–free DNA, next-generation sequencing-based genomic panel analysis including single nucleotide variants, insertions/deletions, copy number variants, and MSI assessment, and the pathologist reviews and signs out the interpreted report. Typical sites of service include outpatient oncology clinics, hospital outpatient laboratories, and reference molecular pathology laboratories. The result integrates into the oncology care workflow to inform treatment planning, clinical trial eligibility, or further tissue testing decisions.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    81445Targeted genomic sequence analysis panel, solid organ neoplasm, DNA analysis, 5-50 genesAlternative or complementary tumor panel testing performed on tissue; may be ordered when tissue is available or to confirm cfDNA findings.

    Related Modifiers

    5 rows

    ModifierDescriptionWhen to Use
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    90Modifier ‑90 (Reference/Outside Laboratory) indicates that a laboratory test was performed by an entity other than the treating or reporting provider. The American Medical Association defines…- Use CPT modifier -90 when a laboratory test is performed by an outside/reference laboratory (an entity other than the treating or reporting physician or qualified professional) and the claim needs…
    82Modifier 82 is appended to a surgical CPT code to indicate that an attending physician acted as an assistant because a qualified resident surgeon was unavailable. In teaching hospitals it documents…- When to use: Append modifier 82 in teaching-hospital settings to indicate a physician served as an assistant surgeon because a qualified resident surgeon was unavailable (includes situations where…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    53Modifier 53 (Discontinued Procedure) signals that a surgical or diagnostic service was begun by the physician but terminated because of extenuating circumstances that threatened the patient’s…- Use modifier -53 when a physician/qualified healthcare professional has started a surgical or diagnostic procedure (e.g., anesthesia administered, incision or scope insertion) and then discontinues…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207ZP0102X
    207ZP0105X
    207L00000X
    2471M1202X
    261QM1103X
    207LA0401X
    2471S1302X
    247100000X

    Related Payer Policy Updates

    Specialty: Genetic & Molecular Testing1 / 3

    10 rows

    PolicyPayerEffective Date
    Minimal Residual Disease (MRD) Testing for Cancerregence2027-01-01
    Biomarker Testing MandateBlue Cross Blue Shield - Rhode Island2027-01-01
    Prenatal (Fetal) Diagnostic TestingBlue Cross Blue Shield - Rhode Island2027-01-01
    Oral Cancer Screening and TestingOscar Health2027-01-01
    RTM Testing for Alpha-1 Antitrypsin DeficiencyOscar Health2027-01-01
    Cytochrome P450 Genotype-Guided Treatment Strategy Corporate Medical Policybcbsvermont2027-01-01
    Cytochrome P450 Genotypingblue cross blue shield - tennessee2026-12-31
    Polygenic Risk ScoreBlue Cross Blue Shield - Rhode Island2026-12-01
    Gene Expression Profiling for Cutaneous MelanomaBlue Cross Blue Shield - Rhode Island2026-12-01
    Genetic Variant Testing (Including Liquid Biopsy) for Targeted Treatment in Advanced Cancerblue_shield_of_california2026-11-01

    Related Codes

    CPT-81410-GENOMIC-PANEL-AORTIC-DISEASE

    CPT 81410: Heritable Thoracic Aortic Disease Targeted Gene Panel

    CPT-81411-GENETIC-DUPLICATION-DELETION-PANEL-AORTIC-DISEASE

    CPT 81411: Genetic Panel for Aortic Dysfunction Copy Number Analysis

    CPT-81412-ASHKENAZI-JEWISH-GENOMIC-SEQUENCE-PANEL

    CPT 81412: Ashkenazi Jewish–Associated Genetic Sequence Panel

    CPT-81413-GENOMIC-PANEL-CARDIAC-ION-CHANNELOPATHIES

    CPT 81413: Cardiac Ion Channelopathy Targeted Gene Panel

    CPT-81414-CARDIAC-ION-CHANNELOPATHY-CNV-PANEL

    CPT 81414: Cardiac Ion Channelopathy Copy Number Variant Panel

    CPT-81415-EXOME-SEQUENCE-ANALYSIS-UNEXPLAINED-DISORDER

    CPT 81415: Exome Sequence Analysis for Unexplained Disorder

    CPT-81416-FAMILIAL-EXOME-SEQUENCE-ANALYSIS

    CPT 81416: Relative Exome Sequence Analysis for Reference Exome

    CPT-81417-EXOME-SEQUENCE-REEVALUATION

    CPT 81417: Exome Reanalysis for New Clinical Information

    CPT-81418-PHARMACOGENOMIC-MULTIGENE-DRUG-METABOLISM-PANEL

    CPT 81418: Pharmacogenetic Multigene Panel Including CYP2C19 and CYP2D6

    CPT-81419-GENOMIC-SEQUENCE-PANEL-EPILEPSY

    CPT 81419: Genomic Sequence Analysis Panel for Epilepsy

    Showing 1–10 of 43

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

    88342
    Immunohistochemistry or immunocytochemistry, per specimen
    Performed on tissue biopsy to assess protein expression (e.g., mismatch repair proteins) that complements MSI assessment from cfDNA.
    88341Immunohistochemistry or immunocytochemistry, each additional single antibody stain procedureUsed when multiple IHC stains are required on tissue to evaluate biomarkers relevant to tumor profiling.
    88360Morphometric analysis, tumor immunohistochemistryQuantitative assessment of IHC results on tissue that can support interpretation of molecular findings.
    81210BRAF gene analysis, V600E variantSingle-gene molecular assay that may be ordered when a specific actionable mutation (BRAF V600E) is suspected or to confirm NGS findings from cfDNA.